Corporate News 16-Aug-18
AstraZeneca Pharma India gets DCGI approval for launch of Olaparib Tablets in India
Astrazeneca Pharma India has received Import and Market permission in Form 45 (Marketing Authorization) from the Drugs Controller General of India for Olaparib Tablets 100 mg and 150 mg (Lynparza®). The receipt of this Import and Market permission paves way for the launch of Olaparib Tablets 100 mg and 150 mg (Lynparza®) in India, subject to the receipt of other related statutory approvals and licenses.
Previous News
Astrazeneca Pharma India fixes record date for interim dividend
( Market Beat - Reports 10-Aug-21 10:00 )
Astrazeneca Pharma India schedules AGM
( Corporate News - 25-Jul-23 09:45 )
Astrazeneca Pharma rises on planning to launch Enhertu
( Hot Pursuit - 21-Dec-23 10:01 )
AstraZeneca hits 52-week high on DCGI nod for Dapagliflozin tablets
( Hot Pursuit - 25-Jul-23 15:00 )
Astrazeneca Pharma India to table results
( Corporate News - 02-Aug-22 10:54 )
Astrazeneca Pharma India to table results
( Corporate News - 31-Oct-23 14:03 )
Astrazeneca Pharma gains after DGCA approves anti-diabetic drug
( Hot Pursuit - 26-Sep-19 10:25 )
Astrazeneca Pharma India schedules AGM
( Corporate News - 18-Jul-20 17:12 )
Astrazeneca Pharma India standalone net profit rises 84.08% in the December 2016 quarter
( Results - Announcements 03-Feb-17 14:16 )
Astrazeneca Pharma India schedules board meeting
( Corporate News - 20-Jan-18 11:57 )
Volumes spurt at Godrej Industries Ltd counter
( Hot Pursuit - 27-May-22 14:30 )
Other Stories
Vardhan Capital & Finance schedules AGM
06-Jul-24 17:34
Automotive Axles schedules AGM
06-Jul-24 17:34
Maruti Infrastructure to conduct AGM
06-Jul-24 17:34
Torrent Power schedules AGM
06-Jul-24 17:34
Raghav Productivity Enhancers to hold AGM
06-Jul-24 17:34
Berger Paints India schedules AGM
06-Jul-24 17:33
Walpar Nutritions to conduct AGM
06-Jul-24 17:33
Weizmann AGM scheduled
06-Jul-24 17:33
Gretex Industries schedules AGM
06-Jul-24 17:33
Karma Energy schedules AGM
06-Jul-24 17:33
Back
Top
